Racial differences in Alzheimer’s disease unveiled

Racial differences in Alzheimer’s disease unveiled

A new study at the School of Medicine finds disparities between African-Americans and Caucasians in a key biomarker for Alzheimer’s disease — suggesting that tools to diagnose the disease in Caucasian populations may not work as well in African-Americans.
Drug compound halts Alzheimer’s-related damage in mice

Drug compound halts Alzheimer’s-related damage in mice

Researchers at the School of Medicine have shown that levels of tau protein can be reduced – and some of the neurological damage caused by tau even reversed ­– by a synthetic molecule that targets genetic instructions. The findings are important for Alzheimer’s and other neurological diseases.
Brain imaging links Alzheimer’s decline to tau protein

Brain imaging links Alzheimer’s decline to tau protein

Using a new imaging agent that binds to tau protein and makes it visible in positron emission tomography (PET) scans, scientists at Washington University School of Medicine in St. Louis have shown that measures of tau are better markers of the cognitive decline characteristic of Alzheimer’s than measures of amyloid beta seen in PET scans.

Bateman receives MetLife Award for Alzheimer’s research

Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at the School of Medicine, has received a MetLife Foundation Award for Medical Research.  Bateman, a leader in Alzheimer’s disease research, is the university’s fifth researcher to receive the prize.
View More Stories